Covered recipient · General Payments record
SAFY M JOHN
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
General Payments · PY2018–2024
$3,717.91
- Reported across 98 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $624.39 | 9 |
| Education | $10.86 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $338.25 | 5 |
| Gilead Sciences, Inc. | $243.68 | 2 |
| ABBVIE INC. | $35.83 | 2 |
| Merck Sharp & Dohme Corporation | $17.49 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.77 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103999377 | CMS |
| ABBVIE INC. | $18.06 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103999379 | CMS |
| AstraZeneca Pharmaceuticals LP | $83.15 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105900014 | CMS |
| AstraZeneca Pharmaceuticals LP | $122.88 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105859664 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.70 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105752271 | CMS |
| AstraZeneca Pharmaceuticals LP | $10.86 | 10/24/2024 | Education | Undisputed | 01/23/2026 | 1104325180 | CMS |
| AstraZeneca Pharmaceuticals LP | $109.66 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105892170 | CMS |
| Gilead Sciences, Inc. | $121.84 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133826729 | CMS |
| Gilead Sciences, Inc. | $121.84 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133826731 | CMS |
| Merck Sharp & Dohme LLC | $17.49 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141612088 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.